​

MiNK Therapeutics (INKT) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

INKT Stock Forecast

MiNK Therapeutics (INKT) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $35.00, with a high of $35.00 and a low of $35.00. This represents a 214.18% increase from the last price of $11.14.

- $7 $14 $21 $28 $35 High: $35 Avg: $35 Low: $35 Last Closed Price: $11.14

INKT Stock Rating

MiNK Therapeutics stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (80.00%), 1 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 1 4 Strong Sell Sell Hold Buy Strong Buy

INKT Price Target Upside V Benchmarks

TypeNameUpside
StockMiNK Therapeutics214.18%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$35.00
Last Closing Price$11.14$11.14$11.14
Upside/Downside--214.18%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 26-2---2
Mar, 26-1---1
Feb, 26-2---2
Jan, 26-2---2
Dec, 25-2---2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 15, 2025Emily BodnarH.C. Wainwright$35.00$28.7521.74%214.18%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 15, 2025H.C. WainwrightNeutralBuyupgrade
Jul 15, 2025H.C. WainwrightNeutraldowngrade
Jul 11, 2025William BlairMarket Performdowngrade

Financial Forecast

EPS Forecast

$-7 $-5 $-3 $-1 $1 $3 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-6.54$-2.90$-2.93---
Avg Forecast$-6.51$-3.65$-2.71$-2.86$-2.70$2.40
High Forecast$-6.31$-3.58$-2.32$-2.61$-2.50$2.40
Low Forecast$-6.71$-3.71$-3.10$-3.11$-2.90$2.40
Surprise %0.46%-20.55%8.12%---

Revenue Forecast

$0 $15M $30M $45M $60M $75M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast----$4.40M$70.40M
High Forecast----$4.40M$70.40M
Low Forecast----$4.40M$70.40M
Surprise %------

Net Income Forecast

$-15B $-11B $-7B $-3B $1B $5B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-22.46M$-10.78M$-12.49B---
Avg Forecast$-223.67M$-125.29M$-93.17M$-98.18M$-92.77M$82.46M
High Forecast$-216.79M$-123.02M$-79.86M$-89.57M$-85.90M$82.46M
Low Forecast$-230.55M$-127.57M$-106.48M$-106.80M$-99.64M$82.46M
Surprise %-89.96%-91.39%13309.77%---

INKT Forecast FAQ

Is MiNK Therapeutics stock a buy?

MiNK Therapeutics stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that MiNK Therapeutics is a favorable investment for most analysts.

What is MiNK Therapeutics's price target?

MiNK Therapeutics's price target, set by 5 Wall Street analysts, averages $35 over the next 12 months. The price target range spans from $35 at the low end to $35 at the high end, suggesting a potential 214.18% change from the previous closing price of $11.14.

How does MiNK Therapeutics stock forecast compare to its benchmarks?

MiNK Therapeutics's stock forecast shows a 214.18% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for MiNK Therapeutics over the past three months?

  • April 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is MiNK Therapeutics’s EPS forecast?

MiNK Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.86, marking a -2.39% decrease from the reported $-2.93 in 2025. Estimates for the following years are $-2.7 in 2027, and $2.4 in 2028.

What is MiNK Therapeutics’s revenue forecast?

MiNK Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $0, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $4.4M, and $70.4M for 2028.

What is MiNK Therapeutics’s net income forecast?

MiNK Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-98.184M, representing a -99.21% decrease from the reported $-12.494B in 2025. Projections indicate $-92.772M in 2027, and $82.46M in 2028.